Garcia-Manero G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:1307–25.
Google Scholar
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.
Google Scholar
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.
Google Scholar
Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Ossa JEA, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evidence. 2022;1:EVIDoa2200008.
Google Scholar
Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao LP, et al. Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes. J Clin Oncol. 2023;41:2827–42.
Google Scholar
Aguirre LE, Al Ali N, Sallman DA, Ball S, Jain AG, Chan O, et al. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes. Leukemia. 2023;37:1530–9.
Google Scholar
Kewan T, Bahaj W, Durmaz A, Aly M, Ogbue OD, Carraway HE, et al. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes. Blood. 2023;141:1768–72.
Google Scholar
Kanagal-Shamanna R, Singh RR, Routbort MJ, Patel KP, Medeiros LJ, Luthra R. Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. Expert Rev Mol Diagn. 2016;16:461–72.
Google Scholar
Aalen O, Borgan O, Gjessing H. Survival and event history analysis: a process point of view. Netherlands: Springer New York; 2008.
Akaike H. Information theory and an extension of the maximum likelihood principle. 2nd International Symposium on Information Theory. Akadémiai Kiadó. 1973;267–81.
Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247:2543–6.
Google Scholar
MDS-HOPE: 6-Group Multivariable Model for Risk Stratifying HMA-Treated MDS Patients. https://biostatistics.mdanderson.org/shinyapps/MDS-HOPE/.
Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020;4:482–95.
Google Scholar
Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. 2017;130:1514–22.
Google Scholar
Sasaki K, Jabbour E, Montalban-Bravo G, Darbaniyan F, Do K-A, Class C, et al. Low-dose decitabine versus low-dose azacitidine in lower-risk MDS. NEJM Evidence. 2022;1:EVIDoa2200034.
Google Scholar
